002773 康弘药业
已收盘 07-19 15:00:00
资讯
新帖
简况
康弘药业最新公告:富马酸伏诺拉生片获得药品注册证书
证券之星 · 07-16
康弘药业最新公告:富马酸伏诺拉生片获得药品注册证书
康弘药业(002773.SZ):富马酸伏诺拉生片获批上市
智通财经 · 07-16
康弘药业(002773.SZ):富马酸伏诺拉生片获批上市
非酒精性脂肪性肝炎(NASH)概念盘中跳水,康弘药业跌5.10%
自选股智能写手 · 07-15
非酒精性脂肪性肝炎(NASH)概念盘中跳水,康弘药业跌5.10%
康弘药业:截至2024年7月10日,公司股东户数为33,070户
证券之星 · 07-11
康弘药业:截至2024年7月10日,公司股东户数为33,070户
阿尔茨海默概念盘中拉升,康弘药业涨1.61%
自选股智能写手 · 07-10
阿尔茨海默概念盘中拉升,康弘药业涨1.61%
康弘药业(002773.SZ):化学原料药枸橼酸托法替布上市申请获批
智通财经 · 07-09
康弘药业(002773.SZ):化学原料药枸橼酸托法替布上市申请获批
康弘药业最新公告:子公司获批枸橼酸托法替布上市
证券之星 · 07-09
康弘药业最新公告:子公司获批枸橼酸托法替布上市
康弘药业最新公告:子公司收到富马酸伏诺拉生化学原料药上市申请批准通知书
证券之星 · 07-05
康弘药业最新公告:子公司收到富马酸伏诺拉生化学原料药上市申请批准通知书
康弘药业(002773.SZ):化学原料药富马酸伏诺拉生上市申请获批
智通财经 · 07-05
康弘药业(002773.SZ):化学原料药富马酸伏诺拉生上市申请获批
康弘药业:截至2024年6月28日,公司股东户数为33,302户
证券之星 · 07-02
康弘药业:截至2024年6月28日,公司股东户数为33,302户
康弘药业新提交2件商标注册申请
证券之星 · 06-29
康弘药业新提交2件商标注册申请
康弘药业:截至2024年6月20日,公司股东户数为33,904户
证券之星 · 06-25
康弘药业:截至2024年6月20日,公司股东户数为33,904户
康弘药业(002773)6月21日主力资金净卖出1123.39万元
证券之星 · 06-24
康弘药业(002773)6月21日主力资金净卖出1123.39万元
康弘药业(002773.SZ)收到缅甸联邦共和国政府卫生部食品药品监督管理局药品注册证书
智通财经 · 06-18
康弘药业(002773.SZ)收到缅甸联邦共和国政府卫生部食品药品监督管理局药品注册证书
康弘药业:盐酸文拉法辛缓释片用于治疗抑郁症(包括伴有焦虑的抑郁症)及广泛性焦虑障碍
证券之星 · 06-13
康弘药业:盐酸文拉法辛缓释片用于治疗抑郁症(包括伴有焦虑的抑郁症)及广泛性焦虑障碍
康弘药业(002773)6月6日主力资金净买入1206.87万元
证券之星 · 06-07
康弘药业(002773)6月6日主力资金净买入1206.87万元
康弘药业:我司KH737由于整体项目规划,目前暂无启动临床研究的计划
证券之星 · 06-04
康弘药业:我司KH737由于整体项目规划,目前暂无启动临床研究的计划
康弘药业(002773.SZ):普拉洛芬滴眼液获药品注册证书
智通财经 · 06-03
康弘药业(002773.SZ):普拉洛芬滴眼液获药品注册证书
康弘药业最新公告:普拉洛芬滴眼液获得药品注册证书
证券之星 · 06-03
康弘药业最新公告:普拉洛芬滴眼液获得药品注册证书
康弘药业:截至2024年5月31日,公司股东户数为35,338户
证券之星 · 06-03
康弘药业:截至2024年5月31日,公司股东户数为35,338户
暂无数据
公司概况
公司名称:
成都康弘药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2015-06-26
主营业务:
成都康弘药业集团股份有限公司主营业务为药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司目前上市产品主要为康柏西普眼用注射液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、右佐匹克隆片等药品和医疗器械。
发行价格:
13.62
{"stockData":{"symbol":"002773","market":"SZ","secType":"STK","nameCN":"康弘药业","latestPrice":21.04,"timestamp":1721372583000,"preClose":21.26,"halted":0,"volume":4996778,"delay":0,"floatShares":685000000,"shares":919000000,"eps":1.2388,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.22,"latestTime":"07-19 15:00:00","open":21.24,"high":21.41,"low":20.96,"amount":106000000,"amplitude":0.0212,"askPrice":21.08,"askSize":12,"bidPrice":21.04,"bidSize":62,"shortable":0,"etf":0,"ttmEps":1.2388,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721611800000},"adr":0,"adjPreClose":21.26,"symbolType":"stock","openAndCloseTimeList":[[1721352600000,1721359800000],[1721365200000,1721372400000]],"highLimit":23.39,"lowLimit":19.13,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":919463954,"pbRate":2.39,"roa":"--","roe":"4.67%","epsLYR":1.14,"committee":-0.134921,"marketValue":19346000000,"floatMarketCap":14413000000,"peRate":16.984178,"changeRate":-0.0103,"turnoverRate":0.0073,"status":1},"requestUrl":"/m/hq/s/002773/tweets","defaultTab":"tweets","newsList":[{"id":"2451196282","title":"康弘药业最新公告:富马酸伏诺拉生片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2451196282","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451196282?lang=zh_cn&edition=full","pubTime":"2024-07-16 18:30","pubTimestamp":1721125843,"startTime":"0","endTime":"0","summary":"康弘药业公告,公司于近日收到国家药品监督管理局签发的关于富马酸伏诺拉生片的《药品注册证书》,批准注册。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071600037021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0197","BK0239","002773"],"gpt_icon":0},{"id":"2451649979","title":"康弘药业(002773.SZ):富马酸伏诺拉生片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2451649979","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451649979?lang=zh_cn&edition=full","pubTime":"2024-07-16 18:26","pubTimestamp":1721125580,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)公告,公司近日收到国家药品监督管理局签发的关于富马酸伏诺拉生片的《药品注册证书》。公告显示,伏诺拉生以钾离子竞争性方式可逆性抑制H+、K+-ATP酶活性,可长时间停留于胃壁细胞部位而抑制胃酸的生成,可有效抑制胃肠道上部粘膜损伤的形成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0196","002773","BK0197"],"gpt_icon":0},{"id":"2451656796","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水,康弘药业跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451656796","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451656796?lang=zh_cn&edition=full","pubTime":"2024-07-15 10:22","pubTimestamp":1721010153,"startTime":"0","endTime":"0","summary":"07月15日,非酒精性脂肪性肝炎(NASH)概念盘中跳水,截至10点22分,非酒精性脂肪性肝炎(NASH)概念整体指数下跌2.02%,报969.530点。从个股上来看,该概念的成分股中,康弘药业跌5.10%,福瑞股份、微芯生物、众生药业跌幅居前。从资金上来看,截止发稿,非酒精性脂肪性肝炎(NASH)概念主力净流入为-3833.63万,其中微芯生物受到资金热捧,主力净流入-30.88万;拉长时间线来看,该板块近20日主力资金净流入-15.34亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240715102233941f6f27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240715102233941f6f27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0196","BK0239","002773","688321","BK0197"],"gpt_icon":0},{"id":"2450336525","title":"康弘药业:截至2024年7月10日,公司股东户数为33,070户","url":"https://stock-news.laohu8.com/highlight/detail?id=2450336525","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450336525?lang=zh_cn&edition=full","pubTime":"2024-07-11 17:03","pubTimestamp":1720688619,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业07月11日在投资者关系平台上答复投资者关心的问题。截至今天7月上旬末公司的股东数目是多少?投资者:请问到7.10股东人数是多少?截至2024年7月10日,公司股东户数为33,070户。感谢您的关注与支持!本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100033504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0197","002773"],"gpt_icon":0},{"id":"2450341882","title":"阿尔茨海默概念盘中拉升,康弘药业涨1.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450341882","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450341882?lang=zh_cn&edition=full","pubTime":"2024-07-10 09:44","pubTimestamp":1720575848,"startTime":"0","endTime":"0","summary":"07月10日,阿尔茨海默概念盘中拉升,截至09点44分,阿尔茨海默概念整体指数上涨0.63%,报1087.880点。从个股上来看,该概念的成分股中,康弘药业涨1.61%,灵康药业、鲁抗医药、双鹭药业涨幅居前。从资金上来看,截止发稿,阿尔茨海默概念概念主力净流入为-32.24万,其中鲁抗医药受到资金热捧,主力净流入534.83万;拉长时间线来看,该板块近20日主力资金净流入-16.11亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710094408af91775d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710094408af91775d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0168","002773","600789","BK0046","BK0196","BK0197","BK0239","BK0188"],"gpt_icon":0},{"id":"2450028854","title":"康弘药业(002773.SZ):化学原料药枸橼酸托法替布上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2450028854","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450028854?lang=zh_cn&edition=full","pubTime":"2024-07-09 21:42","pubTimestamp":1720532521,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)发布公告,公司全资子公司四川弘远药业有限公司于今日收到国家药品监督管理局签发的关于枸橼酸托法替布的《化学原料药上市申请批准通知书》(通知书编号:2024YS00681),批准本品生产。据悉,托法替布是一种Janus激酶(JAK)抑制剂,原研产品于2021年9月在国内首次获批上市,适应症为类风湿关节炎、银屑病关节炎、强直性脊柱炎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0196","002773","BK0197"],"gpt_icon":0},{"id":"2450044072","title":"康弘药业最新公告:子公司获批枸橼酸托法替布上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2450044072","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450044072?lang=zh_cn&edition=full","pubTime":"2024-07-09 20:50","pubTimestamp":1720529438,"startTime":"0","endTime":"0","summary":"康弘药业公告,子公司四川弘远药业有限公司收到国家药品监督管理局签发的枸橼酸托法替布《化学原料药上市申请批准通知书》,批准生产该药品。托法替布是一种Janus激酶抑制剂,适应症包括类风湿关节炎、银屑病关节炎和强直性脊柱炎。此次获批将丰富康弘药业的化学原料药产品线。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070900047324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0197","002773","BK0239"],"gpt_icon":0},{"id":"2449226688","title":"康弘药业最新公告:子公司收到富马酸伏诺拉生化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449226688","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449226688?lang=zh_cn&edition=full","pubTime":"2024-07-05 19:30","pubTimestamp":1720179009,"startTime":"0","endTime":"0","summary":"康弘药业公告,全资子公司四川弘远于今日收到国家药品监督管理局签发的关于富马酸伏诺拉生的《化学原料药上市申请批准通知书》,批准本品生产。富马酸伏诺拉生属于钾离子竞争性阻滞剂,适应症为反流性食管炎。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500042192.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","BK0197","BK0239","BK0196"],"gpt_icon":0},{"id":"2449632932","title":"康弘药业(002773.SZ):化学原料药富马酸伏诺拉生上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2449632932","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449632932?lang=zh_cn&edition=full","pubTime":"2024-07-05 19:17","pubTimestamp":1720178220,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)发布公告,公司全资子公司四川弘远药业有限公司(“四川弘远”)于今日收到国家药品监督管理局签发的关于富马酸伏诺拉生的《化学原料药上市申请批准通知书》(通知书编号:2024YS00666),批准本品生产。据悉,富马酸伏诺拉生属于钾离子竞争性阻滞剂,原研产品于2019年12月在国内首次获批上市,适应症为反流性食管炎。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002773","BK0239","BK0196","BK0197"],"gpt_icon":0},{"id":"2448013294","title":"康弘药业:截至2024年6月28日,公司股东户数为33,302户","url":"https://stock-news.laohu8.com/highlight/detail?id=2448013294","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448013294?lang=zh_cn&edition=full","pubTime":"2024-07-02 19:01","pubTimestamp":1719918100,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业07月02日在投资者关系平台上答复投资者关心的问题。投资者:董秘,您好,请问截止2024年6月28日收盘的股东户数,谢谢。截至2024年6月28日,公司股东户数为33,302户。感谢您的关注与支持!本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200029095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0196","002773","BK0239"],"gpt_icon":0},{"id":"2447271661","title":"康弘药业新提交2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2447271661","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447271661?lang=zh_cn&edition=full","pubTime":"2024-06-29 12:33","pubTimestamp":1719635581,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日成都康弘药业集团股份有限公司新提交2件商标注册申请。商标申请详情如下:今年以来成都康弘药业集团股份有限公司新申请注册商标38件,截止目前公司共持有注册商标842件,另有65件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062900013694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002773","BK0196","BK0239"],"gpt_icon":0},{"id":"2446894401","title":"康弘药业:截至2024年6月20日,公司股东户数为33,904户","url":"https://stock-news.laohu8.com/highlight/detail?id=2446894401","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446894401?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:03","pubTimestamp":1719306189,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)06月25日在投资者关系平台上答复投资者关心的问题。投资者:请问到6.20股东人数是多少康弘药业董秘:尊敬的投资者,您好!截至2024年6月20日,公司股东户数为33,904户。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500033347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","002773","BK0196"],"gpt_icon":0},{"id":"2445009325","title":"康弘药业(002773)6月21日主力资金净卖出1123.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445009325","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445009325?lang=zh_cn&edition=full","pubTime":"2024-06-24 09:14","pubTimestamp":1719191669,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月21日收盘,康弘药业报收于22.33元,上涨2.48%,换手率1.48%,成交量10.12万手,成交额2.26亿元。近5日资金流向一览见下表:康弘药业融资融券信息显示,融资方面,当日融资买入1900.23万元,融资偿还1512.54万元,融资净买入387.69万元。康弘药业主营业务:药品和医疗器械的研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400001878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0197","002773"],"gpt_icon":0},{"id":"2444489548","title":"康弘药业(002773.SZ)收到缅甸联邦共和国政府卫生部食品药品监督管理局药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2444489548","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444489548?lang=zh_cn&edition=full","pubTime":"2024-06-18 19:49","pubTimestamp":1718711351,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)公告,公司全资子公司成都康弘生物科技有限公司(简称“康弘生物”)以及中国国际医药卫生有限公司(公司在缅甸联邦共和国(简称“缅甸”)的独家注册、经销商)于近日收到缅甸政府卫生部食品药品监督管理局签发的朗沐(康柏西普眼用注射液)药品注册证书(注册证编号:2904EA04238)。据悉,康柏西普眼用注射液是公司全资子公司康弘生物自主研发的具有完全自主知识产权的1类生物创新药,该产品能有效地与血管及组织中的VEGF结合,阻断由VEGF介导的促进新生血管出芽和生长的信号传递。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0196","BK0197","002773"],"gpt_icon":0},{"id":"2443092425","title":"康弘药业:盐酸文拉法辛缓释片用于治疗抑郁症(包括伴有焦虑的抑郁症)及广泛性焦虑障碍","url":"https://stock-news.laohu8.com/highlight/detail?id=2443092425","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443092425?lang=zh_cn&edition=full","pubTime":"2024-06-13 19:01","pubTimestamp":1718276498,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业06月13日在投资者关系平台上答复投资者关心的问题。公司将严格按照相关法律法规的规定和要求真实、准确、完整、及时、公平地履行信息披露义务,详细情况敬请关注公司披露的相关公告。投资者:请问公司盐酸文拉法辛缓释片在2022年和2023年的销售额为多少?盐酸文拉法辛缓释片用于治疗抑郁症及广泛性焦虑障碍。单品种销售数据涉及商业秘密,不便公开披露,敬请谅解。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300035012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002773","BK0196","BK0239"],"gpt_icon":0},{"id":"2441708362","title":"康弘药业(002773)6月6日主力资金净买入1206.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2441708362","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441708362?lang=zh_cn&edition=full","pubTime":"2024-06-07 09:12","pubTimestamp":1717722745,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月6日收盘,康弘药业报收于23.47元,上涨3.26%,换手率3.19%,成交量21.83万手,成交额5.18亿元。近5日资金流向一览见下表:康弘药业融资融券信息显示,融资方面,当日融资买入3929.04万元,融资偿还2597.89万元,融资净买入1331.15万元,连续3日净买入累计1823.06万元。康弘药业主营业务:药品和医疗器械的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700012095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","002773","BK0197"],"gpt_icon":0},{"id":"2440400068","title":"康弘药业:我司KH737由于整体项目规划,目前暂无启动临床研究的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2440400068","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440400068?lang=zh_cn&edition=full","pubTime":"2024-06-04 18:04","pubTimestamp":1717495459,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)06月04日在投资者关系平台上答复投资者关心的问题。投资者:听闻KH737暂未启动临床,该管线获批临床到现在近两年时间了,是什么原因导致KH737暂未启动临床呢?康弘药业董秘:尊敬的投资者,您好!我司KH737由于整体项目规划,目前暂无启动临床研究的计划。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060400034938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","BK0196","BK0239","BK0197"],"gpt_icon":0},{"id":"2440246403","title":"康弘药业(002773.SZ):普拉洛芬滴眼液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2440246403","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440246403?lang=zh_cn&edition=full","pubTime":"2024-06-03 20:00","pubTimestamp":1717416016,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)发布公告,公司于近日收到国家药品监督管理局签发的关于普拉洛芬滴眼液的《药品注册证书》(证书编号:2024S00993),批准注册。据悉,普拉洛芬滴眼液属于非甾体抗炎药,具有抑制前列腺素的生成和稳定溶酶体膜的作用,适应症为外眼及眼前节炎症的对症治疗(眼睑炎、结膜炎、角膜炎、巩膜炎、浅层巩膜炎、虹膜睫状体炎、术后炎症)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002773","BK0196","BK0239","BK0197"],"gpt_icon":0},{"id":"2440461781","title":"康弘药业最新公告:普拉洛芬滴眼液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2440461781","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440461781?lang=zh_cn&edition=full","pubTime":"2024-06-03 19:39","pubTimestamp":1717414787,"startTime":"0","endTime":"0","summary":"康弘药业公告,收到国家药品监督管理局签发的关于普拉洛芬滴眼液的《药品注册证书》,批准注册。适应症为外眼及眼前节炎症的对症治疗。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060300025705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002773","BK0239","BK0196"],"gpt_icon":0},{"id":"2440469688","title":"康弘药业:截至2024年5月31日,公司股东户数为35,338户","url":"https://stock-news.laohu8.com/highlight/detail?id=2440469688","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440469688?lang=zh_cn&edition=full","pubTime":"2024-06-03 19:02","pubTimestamp":1717412531,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业06月03日在投资者关系平台上答复投资者关心的问题。投资者:请问公司截至5月31日股东户数是多少?投资者:请教公司,5月底股东人数情况。截至2024年5月31日,公司股东户数为35,338户。感谢您的关注与支持!本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060300023992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002773","BK0239","BK0196"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-06-26","address":"四川省成都市金牛区蜀西路108号","stockEarnings":[{"period":"1week","weight":-0.0479},{"period":"1month","weight":-0.0675},{"period":"3month","weight":0.2417},{"period":"6month","weight":0.2861},{"period":"1year","weight":0.2658},{"period":"ytd","weight":0.1724}],"companyName":"成都康弘药业集团股份有限公司","boardCode":"AI0027","perCapita":"20713股","boardName":"医药制造业","registeredCapital":"91946万元","compareEarnings":[{"period":"1week","weight":0.0023},{"period":"1month","weight":-0.0175},{"period":"3month","weight":-0.0288},{"period":"6month","weight":0.0511},{"period":"1year","weight":-0.0693},{"period":"ytd","weight":0.0007}],"survey":" 成都康弘药业集团股份有限公司主营业务为药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司目前上市产品主要为康柏西普眼用注射液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、右佐匹克隆片等药品和医疗器械。","serverTime":1721403292727,"listedPrice":13.62,"stockholders":"33070人(较上一季度减少0.70%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康弘药业,002773,康弘药业股票,康弘药业股票老虎,康弘药业股票老虎国际,康弘药业行情,康弘药业股票行情,康弘药业股价,康弘药业股市,康弘药业股票价格,康弘药业股票交易,康弘药业股票购买,康弘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}